Oksana Koneva

Solid Biosciences unveils POLARIS-101 next-generation capsid for gene therapy delivery

Solid Biosciences unveils POLARIS-101 next-generation capsid for gene therapy delivery
Solid Biosciences unveils POLARIS-101 capsid

Solid Biosciences has introduced POLARIS-101, a proprietary next-generation muscle-tropic capsid designed to enhance safe, efficient, and scalable delivery of genetic medicines across neuromuscular and cardiac diseases.

The company states that this innovation could transform gene therapy delivery by improving targeting and effectiveness for a broad range of genetic conditions.

Solid Biosciences previously announced plans to present new research on the POLARIS-101 capsid at a leading neuromuscular meeting. The company will also share updates on its INSPIRE DUCHENNE study, according to earlier disclosures. These developments show ongoing efforts to expand the application of gene therapies in neuromuscular disease.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.